S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer

SWOG Cancer Research Network112 enrolled

Overview

RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one chemotherapy drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cyclophosphamide together with capecitabine works in treating women with stage IV breast cancer.

OBJECTIVES: * Determine the response rate (complete and partial, confirmed and unconfirmed) in women with stage IV breast cancer treated with oral cyclophosphamide and oral capecitabine. * Determine the progression-free survival and overall survival of patients treated with this regimen. * Determine the toxicity of this regimen in these patients. * Determine the quality of life of patients treated with this regimen. OUTLINE: This is a multicenter study. Patients receive oral cyclophosphamide once daily on days 1-14 and oral capecitabine twice daily on days 8-21. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then at weeks 7, 13, 19, and 25. After completion of study treatment, patients are followed every 3 months for up to 2 years. PROJECTED ACCRUAL: A total of 96 patients will be accrued for this study within 4 years.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

112

Conditions

Breast Cancer

Interventions

capecitabineDRUG

cyclophosphamideDRUG

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed stage IV breast cancer * Metastatic disease (M1) OR multiple sites of new disease that is clinically obvious metastatic disease (i.e., multiple sites of new osseous disease) * Meets 1 of the following criteria: * Measurable disease * Non-measurable disease * MUC-1 antigen level \> 2 times upper limit of normal AND level has increased by 1.5 times * Must have documented MUC-1 antigen level * Either cancer antigen (CA) 15-3 or CA 27-29 allowed * Must have received at least 1 prior hormonal therapy for metastatic disease (estogen receptor-positive patients only) * No symptomatic brain or CNS metastases * Previously treated brain or CNS metastasis allowed provided radiotherapy was completed ≥ 8 weeks before study entry * Hormone receptor status: * Not specified PATIENT CHARACTERISTICS: Age * 18 and over Sex * Female Menopausal status * Not specified Performance status * Zubrod 0-2 Life expectancy * Not specified Hematopoietic * No known existing uncontrolled coagulopathy Hepatic * Not specified Renal * Creatinine clearance \> 40 mL/min Cardiovascular * No congestive heart failure * No symptomatic coronary artery disease * No cardiac arrhythmia not well controlled with medication * No myocardial infarction within the past 12 months * No other clinically significant cardiac disease Gastrointestinal * Able to take oral medication * No uncontrolled nausea, vomiting, or diarrhea * No lack of physical integrity of the upper gastrointestinal tract * No malabsorption syndrome Other * Not pregnant or nursing * Fertile patients must use effective contraception * No active infection requiring systemic therapy * No prior severe reaction to fluoropyrimidines * No known sensitivity to fluorouracil * No known dihydropyrimidine dehydrogenase deficiency * No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy * No concurrent immunotherapy or biologic therapy for breast cancer * No concurrent gene therapy for breast cancer * No concurrent filgrastim (G-CSF) Chemotherapy * At least 14 days since prior chemotherapy and recovered * No more than 2 prior chemotherapy regimens for metastatic disease * No prior capecitabine for metastatic disease * No prior oral cyclophosphamide for metastatic disease * Prior IV cyclophosphamide allowed * No other concurrent chemotherapy for breast cancer Endocrine therapy * See Disease Characteristics * No concurrent hormonal therapy for breast cancer Radiotherapy * See Disease Characteristics * At least 14 days since prior radiotherapy to non-CNS disease sites and recovered * No concurrent radiotherapy for breast cancer Surgery * Not specified Other * Concurrent bisphosphonates allowed * No concurrent full-dose warfarin * Concurrent prophylactic warfarin (≤ 1 mg/day) to maintain port patency allowed * No other concurrent antineoplastic therapy for breast cancer

Locations (145)

Outcomes

Primary Outcomes

Response Rate (Complete and Partial, Confirmed and Unconfirmed)

Complete Response (CR) is complete disappearance of all measurable and non-measurable disease. No new lesions, no disease related symptoms. Normalization of markers and other abnormal lab values. Partial Response (PR) is greater than or equal to 30% decrease under baseline of the sum of longest diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. Confirmation of CR or PR means a repeat scan at least 4 weeks apart documented before progression or symptomatic deterioration. Progression is 20% increase in sum of longest diameters of target measurable lesions over smallest sum observed and/or unequivocal progression of non-measurable disease and/or appearance of new lesion/site or death due to disease without prior documentation of progression and without symptomatic deterioration. Symptomatic deterioration is global deterioration of health status requiring discontinuation of treatment without objective evidence of progression.

Time frame: Patients assessed at least every six weeks while on protocol treatment

Secondary Outcomes

Progression-free Survival and Overall Survival

Progression-Free Survival: From date of registration to time of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free are censored at last date of contact. Overall Survival: From date of registration to date of death due to any cause. Patients last known to be alive are censored at last date of contact. Progression is 20% increase in sum of longest diameters of target measurable lesions over smallest sum observed and/or unequivocal progression of non-measurable disease and/or appearance of new lesion/site or death due to disease without prior documentation of progression and without symptomatic deterioration. Symptomatic deterioration is global deterioration of health status requiring discontinuation of treatment without objective evidence of progression.

Time frame: two years

Toxicity

Number of patients for whom Grade 3 or higher toxicity observed during treatment. Only adverse events that are possibly, probably or definitely related to study drug are reported.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Alaska Regional Hospital Cancer Center

Anchorage, Alaska, United States

Providence Cancer Center

Anchorage, Alaska, United States

Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Eden Medical Center

Castro Valley, California, United States

Kaiser Permanente - Fremont

Fremont, California, United States

Kaiser Permanente Medical Center - Hayward

Hayward, California, United States

Saint Rose Hospital

Hayward, California, United States

Highland General Hospital

Oakland, California, United States

Alta Bates Summit Medical Center - Summit Campus

Oakland, California, United States

CCOP - Bay Area Tumor Institute

Oakland, California, United States

...and 135 more locations